塞来昔布作为增敏剂联合125I粒子植入治疗肺癌的近期疗效观察

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To observe the short-term efficacy for celecoxib as a sensitization agent for 125I particles implantation in the treatment of lung cancer. Methods: Sixty-six patients with lung cancer were treated by CT guided interstitial 125I particles implantation． They were randomly divided into two groups(33 patients in test group, the other 33 in control group). The test group was given celecoxib on the same day of 125I particles implantation. The control group was only implanted with 125I particles. The local control of the tumor(complete relief+partial relief) was used as an evaluation standard of curative effect. Results: Among the 33 patients in the test group(125I particles implanted with celecoxib as radiotherapy sensitization agent), 3 patients had complete relief, 24 patients had partial relief, 3 patients had no effect and 3 patients had slight relief. The short-term effective rate was 81.8%. In the control group(33 cases with implanted 125I particles only): 1 patient had complete relief, 19 patients had partial relief, 3 patients had slight relief and 3 patients had no effect. The recent effective rate was 60.6%. The difference between the two groups was statistically significant(P<0.05). Conclusion: The treatment of celecoxib combined with 125I particles implantation for lung cancer has good radiotherapy sensitization effect. It improves the local control rate of tumor and has fewer side effects and is safe and effective.

Key words： Lung neoplasms Radionuclide imaging Tomography, X-ray computed

Received: 26 September 2016

PACS:	Ｒ734.2
	Ｒ817.4
	Ｒ814.42

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Shuang
	LIU Bao-ping
	CHANG Wei
	WANG Rui-hua
	XIE Xin-li
	CHENG Bing
	HAN Xing-min
	RUAN Qiao

Cite this article:

LI Shuang,LIU Bao-ping,CHANG Wei, et al. Observation of the short-term efficacy for celecoxib as a sensitization agent for#br# 125I particles implantation in the treatment of lung cancer[J]. JOURNAL OF CHINA MEDICAL IMAGING, 2017, 28(6): 408-411.

URL:

http://www.jccmi.com.cn/EN/ OR http://www.jccmi.com.cn/EN/Y2017/V28/I6/408

[1]王俊杰，黄毅，冉维强，等．放射性粒子组织间种植近治疗肿瘤近期疗效[J]．中国微创外科杂志，2003，3（2）：148-149．
[2]Lee W, Daly BD, DiPetrillo TA, et al. Limited resection for non-small cell lung cancer: observed local control with implantation of I-125 brachytherapy seeds[J]． Ann Thorac Surg, 2003, 75(1): 237-242.
[3]Birdas TJ, Koehler RP, Colonias A, et al. Sublobar resection with brachytherapy versus lobectomy for stage Ib non-small cell lung cancer[J]． Ann Thorac Surg, 2006, 81(2): 434-438.
[4]李小东，李亚明．重视放射性粒子植入治疗的规范化[J]．中华核医学与分子影像杂志，2013，33（4）：241-242．
[5]中华医学会．临床技术操作规范：放射肿瘤学分册[M]．北京：人民军医出版社，2006：117．
[6]胡清，吴清明，马玉芳，等. 环氧合酶-2选择性抑制剂联合放疗治疗晚期食管癌的近期疗效观察[J]. 实用医学杂志，2006，22（9）：1066-1067.
[7]向银洲，余林，魏莲枝，等. 塞来昔布对鼻咽癌放射治疗增敏作用的临床研究[J]. 中国耳鼻咽喉头颈外科，2012，19（1）：16.
[8]王俊杰，庄永志. 放射性粒子近距离治疗肿瘤[J]. 中国微创外科杂志，2001，1（3）：187-191.
[9]Souza CD, Rostelato MECM, Zeituni CA, et al. Analysis of the necessary radioprotection procedures in manufacture of iodine-125 sources used in brachytherapy: A preliminary study[J]. Progr Nucl Energy, 2011, 53(1): 66-72.
[10]Colonias A, Betler J, Trombetta M, et al. Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2011, 79(1): 105-109.
[11]Sylvester JE, Grimm PD, Wong J, et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125), prostate brachytherapy in clinically localized prostate cancer: Seattle experience[J]. Int J Radiat Oncol Biol Phys, 2011, 81(2): 376-381.
[12]Ma ZH, Yang Y, Zou L, et al. 125I seed irradiation induces up-regulation of the genes associated with apoptosis and cell cycle arrest and inhibits growth of gastric cancer xenografts[J]. J Exp Clin Cancer Res, 2012, 31(1): 1-10.
[13]Shi L, Wu C, Wu J, et al. Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer[J]. Radiat Oncol, 2012, 7(1): 1-10.
[14]Bansal SS, Joshi A, Bansal AK, et al. New dosage for targeted delivery of cyclooxygenase-2 inhibitors: focus on use in the elderly[J]． Drugs Aging, 2007, 24(6): 441.
[15]韩志强. 选择性环氧化酶-2抑制剂联合放射治疗对肺癌A549细胞作用的实验研究[D]. 苏州：苏州大学，2009.
[16]Morita Y, Morita N, Hata K, et al. Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-c and lymph node metastasis in human oral tongue cancer[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2014, 117(4): 502-510.
[17]Hunter NR, Valdecanas D, Liao Z, et al. Mitigation and treatment of radiation-induced thoracic injury with a cyclooxygenase-2 inhibitor, celecoxib[J]. Int J Radiat Oncol Biol Phys, 2013, 85(2): 472-476.
[18]Griffin RJ, Koonce NA, Dings RPM, et al. Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide[J]. Radiat Res, 2012, 177(6): 804-812.
[19]Thakkar A, Chenreddy S, Wang J, et al. Evaluation of ibuprofen loaded solid lipid nanoparticles and its combination regimens for pancreatic cancer chemoprevention[J]. Int J Oncol, 2015, 46(4): 1827-1834.
[20]Chang WS, Liao CH, Miao CE, et al. The role of functional polymorphisms of cyclooxygenase 2 in renal cell carcinoma[J]. Anticancer Res, 2014, 34(10): 5481-5486.
[21]Mouradian M, Kikawa KD, Johnson ED, et al. Key roles for GRB2-associated-binding protein 1, phosphatidylinositol-3-kinase, cyclooxygenase 2, prostaglandin E2 and transforming growth factor alpha in linoleic acid-induced upregulation of lung and breast cancer cell growth[J]. Prostaglandins Leukot Essent Fatty Acids, 2014, 90(4): 105-115.